(5E)-5-[[8-fluoro-4-[(4-fluorophenyl)methyl]-3-oxo-1,4-benzoxazin-6-yl]methylidene]-1,3-thiazolidine-2,4-dione

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶嗪类
• 英文名称: (5E)-5-[[8-fluoro-4-[(4-fluorophenyl)methyl]-3-oxo-1,4-benzoxazin-6-yl]methylidene]-1,3-thiazolidine-2,4-dione
• 化学式: C₁₉H₁₂F₂N₂O₄S
• 分子量: 402.4
• InChiKey: VURYUBYVGMHUIW-VIZOYTHASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  28
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  101
• 氢给体数：
  1
• 氢受体数：
  7

文献信息

• Benzoxazin-3-ones and derivatives thereof as therapeutic agents
  申请人：——

  公开号：US20040121996A1

  公开（公告）日：2004-06-24

  The present invention provides compounds of Formula I 1 wherein W, Q, E, D, R 6 , R 7 , R 8 , Y, K, R 9 , R 10 , R 12 , G, and the double bond denoted “*” have any of the values defined therefore in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cardiovascular diseases, and cancers. Also provided are pharmaceutical compositions comprising one or more compounds of Formula I.

  本发明提供了I式化合物，其中W，Q，E，D，R6，R7，R8，Y，K，R9，R10，R12，G和表示为“*”的双键具有规范中定义的任何值，并且其药学上可接受的盐，可用作治疗疾病和病症的药物，包括炎症性疾病，心血管疾病和癌症。还提供了包含一种或多种I式化合物的制药组合物。
• BENZOXAZIN-3-ONES AND DERIVATIVES THEREOF AS INHIBITORS OF PI3K
  申请人：Warner-Lambert Company LLC

  公开号：EP1569653A1

  公开（公告）日：2005-09-07
• US7205295B2
  申请人：——

  公开号：US7205295B2

  公开（公告）日：2007-04-17
• [EN] BENZOXAZIN-3-ONES AND DERIVATIVES THEREOF AS INHIBITORS OF PI3K<br/>[FR] BENZOXAZIN-3-ONES ET DERIVES DE CEUX-CI UTILISES EN TANT QU'INHIBITEURS DE PI3K
  申请人：WARNER LAMBERT CO

  公开号：WO2004052373A1

  公开（公告）日：2004-06-24

  The present invention provides compounds of Formula (I) wherein W, Q, E, D, R6, R7, R8, Y, K, R9, R1O, R12, G, and the double bond denoted '*' have any of the values defined therefore in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cardiovascular diseases, and cancers. Also provided are pharmaceutical compositions comprising one or more compounds of Formula (I). The compounds are inhibitors of phosphoinsitide-3-kinase (P13K).